In response to the global coronavirus outbreak, we have implemented a strict visitor policy to safeguard the health and wellbeing of the whole school community. Please read our visitor policy before you visit the school.

Read Visitor Policy

What are the boffins doing about infectious diseases?

What are the boffins doing about infectious diseases?

On Wednesday 15 February at 7pm, we will welcome Old Peterite Professor Mike Ferguson to St Peter’s School, to deliver a lecture entitled ‘What are the boffins doing about infectious diseases?’.

What are the boffins doing about infectious diseases?

Professor Mike Ferguson is a researcher who specialises in parasitic diseases, like human African sleeping sickness and malaria, and who helps to run a Drug Discovery Unit. In this lecture, Professor Ferguson will explain what he and his colleagues are doing to 'translate' fundamental discovery science into new, better and safer medicines for infectious diseases and to tackle the spread of drug-resistant infections, which is a global challenge.

Tickets for the lecture are free and are available on our Eventbrite page. If you have any enquiries or accessibility requirements please telephone us on 01904 527315 or email

Please either print off your ticket or display it to us on your smartphone or tablet on the evening.

Click here to view the event poster

About the speaker

Mike Ferguson

Mike Ferguson left St Peter's School in 1975 and studied Biochemistry in Manchester (BSc) and London (PhD). He worked as a post-doctoral researcher in New York and Oxford before being appointed a lecturer at The University of Dundee in 1988.  Mike was fortunate enough to make a significant biological discovery relatively early in his career and to have subsequently lead a sizeable research team performing both fundamental discovery science and 'translational' applied science - making new drugs and diagnostic devices for infectious diseases. He now also helps shape National and International biomedical research by serving on the boards of the Wellcome Trust and the Medicines for Malaria Venture.